Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2000 1
2002 2
2003 3
2004 3
2005 3
2006 3
2007 2
2008 1
2009 4
2010 5
2011 9
2012 5
2013 9
2014 9
2015 4
2016 9
2017 14
2018 5
2019 12
2020 7
2021 8
2022 18
2023 14
2024 7
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Comparative sensitivity of early cystic fibrosis lung disease detection tools in school aged children.
Bayfield KJ, Weinheimer O, Middleton A, Boyton C, Fitzpatrick R, Kennedy B, Blaxland A, Jayasuriya G, Caplain N, Wielpütz MO, Yu L, Galban CJ, Robinson TE, Bartholmai B, Gustafsson P, Fitzgerald D, Selvadurai H, Robinson PD. Bayfield KJ, et al. Among authors: selvadurai h. J Cyst Fibros. 2024 Sep;23(5):918-925. doi: 10.1016/j.jcf.2024.05.012. Epub 2024 Jul 4. J Cyst Fibros. 2024. PMID: 38969602 Free article.
Exercise testing for young athletes.
Fitzgerald H, Fitzgerald DA, Selvadurai H. Fitzgerald H, et al. Among authors: selvadurai h. Paediatr Respir Rev. 2023 Dec 19:S1526-0542(23)00082-9. doi: 10.1016/j.prrv.2023.12.002. Online ahead of print. Paediatr Respir Rev. 2023. PMID: 38176989 Review.
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M; VX17-445-105 Study Group. Daines CL, et al. Among authors: selvadurai h. Eur Respir J. 2023 Dec 7;62(6):2202029. doi: 10.1183/13993003.02029-2022. Print 2023 Dec. Eur Respir J. 2023. PMID: 37945033 Free PMC article. Clinical Trial.
135 results